Welcome to
RBP World!
Description
| Ensembl ID | ENSG00000169174 | Gene ID | 255738 | Accession | 20001 |
| Symbol | PCSK9 | Alias | FH3;PC9;FHCL3;NARC1;LDLCQ1;NARC-1;HCHOLA3 | Full Name | proprotein convertase subtilisin/kexin type 9 |
| Status | Confidence | Length | 25406 bases | Strand | Plus strand |
| Position | 1 : 55039447 - 55064852 | RNA binding domain | N.A. | ||
| Summary | This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014] | ||||
RNA binding domains (RBDs)
| Protein | Domain | Pfam ID | E-value | Domain number |
|---|
RNA binding proteomes (RBPomes)
| Pubmed ID | Full Name | Cell | Author | Time | Doi |
|---|
Literatures on RNA binding capacity
| Pubmed ID | Title | Author | Time | Journal |
|---|---|---|---|---|
| 36087240 | PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. | Natalie Arnold | 2022-11-01 | Current cardiology reports |
| 36983444 | Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice. | Giosiana Bosco | 2023-03-22 | Journal of clinical medicine |
| 37435056 | Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events. | Ruixing Zhang | 2023-01-01 | Frontiers in cardiovascular medicine |
| 33089390 | Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). | David Sinning | 2020-10-21 | Current cardiology reports |
| 36678807 | Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy. | Yongguang Gao | 2023-01-04 | Pharmaceutics |
| 34514551 | Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice. | Maddalena Rossi | 2022-03-01 | American journal of cardiovascular drugs : drugs, devices, and other interventions |
| 35625707 | New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. | Leo Achim Burger | 2022-04-22 | Biomedicines |
| 37456766 | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control. | Rishi Rikhi | 2023-01-01 | European cardiology |
| 35303294 | Contemporary Management of Dyslipidemia. | A Richard Ferraro | 2022-04-01 | Drugs |
| 35832698 | Influence of lipid-lowering drugs on inflammation: what is yet to be done? | Sabina Ugovšek | 2022-01-01 | Archives of medical science : AMS |
| 28264867 | A New Approach to PCSK9 Therapeutics. | Nan Wang | 2017-03-31 | Circulation research |
| 36213094 | New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. | Paul Sean Gaine | 2022-09-01 | Current cardiovascular risk reports |
| 34070931 | PCSK9 Biology and Its Role in Atherothrombosis. | Cristina Barale | 2021-05-30 | International journal of molecular sciences |
| 28025677 | PCSK9 inhibition: the dawn of a new age in cholesterol lowering? | David Preiss | 2017-03-01 | Diabetologia |
| 34868544 | Novel therapeutic targets and agents for pediatric dyslipidemia. | Bhuvana Sunil | 2021-01-01 | Therapeutic advances in endocrinology and metabolism |
| 29794992 | Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. | Kazutoshi Sugiyama | 2018-05-24 | Diseases (Basel, Switzerland) |
| 27959715 | A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. | Kevin Fitzgerald | 2017-01-05 | The New England journal of medicine |
| 29644225 | FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors. | Mohamed Hassan | 2017-06-30 | Global cardiology science & practice |
| 29562587 | Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. | Giovanni Ciccarelli | 2018-03-17 | Diseases (Basel, Switzerland) |
| 30011788 | Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. | E Constantine Kosmas | 2018-07-13 | Diseases (Basel, Switzerland) |
| 29209403 | Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy. | E Constantine Kosmas | 2017-01-01 | Drugs in context |
| 36717882 | Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. | Toshiyuki Nishikido | 2023-01-30 | Cardiovascular diabetology |
| 36289901 | Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis. | V Anastasia Poznyak | 2022-10-20 | Biomedicines |
| 21938413 | Familial hypercholesterolemia: present and future management. | B Sjouke | 2011-12-01 | Current cardiology reports |
| 24987256 | Familial hypercholesterolemia: A review. | J Mithun Varghese | 2014-05-01 | Annals of pediatric cardiology |
| 33177004 | In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake. | Takehiro Ando | 2021-03-01 | Journal of bioscience and bioengineering |
| 36831039 | Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis. | V Anastasia Poznyak | 2023-02-09 | Biomedicines |
Transcripts
| Name | Transcript ID | bp | Protein | Translation ID |
|---|---|---|---|---|
| PCSK9-204 | ENST00000673726 | 1204 | 204aa | ENSP00000501004 |
| PCSK9-207 | ENST00000710286 | 3729 | 811aa | ENSP00000518176 |
| PCSK9-206 | ENST00000673913 | 3833 | 589aa | ENSP00000501161 |
| PCSK9-201 | ENST00000302118 | 3637 | 692aa | ENSP00000303208 |
| PCSK9-205 | ENST00000673903 | 3194 | 567aa | ENSP00000501257 |
| PCSK9-203 | ENST00000673662 | 603 | No protein | - |
| PCSK9-202 | ENST00000490692 | 3891 | No protein | - |
Phenotypes
| ensgID | Trait | pValue | Pubmed ID |
|---|---|---|---|
| 17330 | Cholesterol, LDL | 4.34e-005 | 19060910 |
| 66396 | Cholesterol | 2E-39 | 24097068 |
| 78281 | Wilms Tumor | 1E-7 | 22544364 |
| 78924 | Hydroxymethylglutaryl CoA Reductases | 5E-9 | 22331829 |
| 78925 | Cholesterol, LDL | 5E-9 | 22331829 |
| 83729 | Cholesterol, LDL | 3E-50 | 24097068 |
| 95340 | Cholesterol, LDL | 2E-28 | 20686565 |
| 95581 | Lipoproteins | 3E-61 | 27005778 |
| 95582 | Metabolism | 3E-61 | 27005778 |
| 98550 | Cholesterol, LDL | 2E-92 | 25961943 |
| 100963 | Cholesterol | 4E-24 | 20686565 |
| 102062 | Cholesterol, LDL | 2E-44 | 18193044 |
GWAS
| ensgID | SNP | Chromosome | Position | Trait | PubmedID | Or or BEAT | EFO ID |
|---|
Protein-Protein Interaction (PPI)
Paralogs
| Ensembl ID | Source | Target | ||||||
|---|---|---|---|---|---|---|---|---|
| Species | Protein ID | Perc_pos | Perc_id | Species | Protein ID | Perc_pos | Perc_id | |
Orthologs
| Ensembl ID | Source | Target | ||||||
|---|---|---|---|---|---|---|---|---|
| Species | Protein ID | Perc_pos | Perc_id | Species | Protein ID | Perc_pos | Perc_id | |
Gene Ontology
| Go ID | Go term | No. evidence | Entries | Species | Category |
|---|---|---|---|---|---|
| GO:0001822 | involved_in kidney development | 1 | ISS | Homo_sapiens(9606) | Process |
| GO:0001889 | involved_in liver development | 1 | ISS | Homo_sapiens(9606) | Process |
| GO:0001920 | involved_in negative regulation of receptor recycling | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0002091 | involved_in negative regulation of receptor internalization | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0002092 | involved_in positive regulation of receptor internalization | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0003723 | enables RNA binding | 1 | HDA | Homo_sapiens(9606) | Function |
| GO:0004252 | enables serine-type endopeptidase activity | 2 | IBA,IDA | Homo_sapiens(9606) | Function |
| GO:0005515 | enables protein binding | 1 | IPI | Homo_sapiens(9606) | Function |
| GO:0005576 | located_in extracellular region | 1 | TAS | Homo_sapiens(9606) | Component |
| GO:0005615 | is_active_in extracellular space | 2 | IBA,IDA | Homo_sapiens(9606) | Component |
| GO:0005737 | located_in cytoplasm | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0005764 | located_in lysosome | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0005765 | located_in lysosomal membrane | 1 | TAS | Homo_sapiens(9606) | Component |
| GO:0005769 | located_in early endosome | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0005770 | located_in late endosome | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0005783 | located_in endoplasmic reticulum | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0005788 | located_in endoplasmic reticulum lumen | 1 | TAS | Homo_sapiens(9606) | Component |
| GO:0005794 | located_in Golgi apparatus | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0005886 | located_in plasma membrane | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0006641 | involved_in triglyceride metabolic process | 1 | IEA | Homo_sapiens(9606) | Process |
| GO:0006644 | involved_in phospholipid metabolic process | 1 | IEA | Homo_sapiens(9606) | Process |
| GO:0006915 | involved_in apoptotic process | 1 | IEA | Homo_sapiens(9606) | Process |
| GO:0007041 | involved_in lysosomal transport | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0008203 | involved_in cholesterol metabolic process | 1 | IEA | Homo_sapiens(9606) | Process |
| GO:0009267 | involved_in cellular response to starvation | 1 | ISS | Homo_sapiens(9606) | Process |
| GO:0009986 | located_in cell surface | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0010469 | involved_in regulation of signaling receptor activity | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0010989 | involved_in negative regulation of low-density lipoprotein particle clearance | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0016540 | involved_in protein autoprocessing | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0019871 | enables sodium channel inhibitor activity | 1 | IDA | Homo_sapiens(9606) | Function |
| GO:0022008 | involved_in neurogenesis | 1 | ISS | Homo_sapiens(9606) | Process |
| GO:0030134 | located_in COPII-coated ER to Golgi transport vesicle | 1 | IEA | Homo_sapiens(9606) | Component |
| GO:0030169 | enables low-density lipoprotein particle binding | 1 | ISS | Homo_sapiens(9606) | Function |
| GO:0030182 | involved_in neuron differentiation | 1 | ISS | Homo_sapiens(9606) | Process |
| GO:0030547 | enables signaling receptor inhibitor activity | 1 | IDA | Homo_sapiens(9606) | Function |
| GO:0031232 | located_in extrinsic component of external side of plasma membrane | 1 | IC | Homo_sapiens(9606) | Component |
| GO:0032802 | involved_in low-density lipoprotein particle receptor catabolic process | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0032805 | involved_in positive regulation of low-density lipoprotein particle receptor catabolic process | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:0032869 | involved_in cellular response to insulin stimulus | 1 | ISS | Homo_sapiens(9606) | Process |
| GO:0034185 | enables apolipoprotein binding | 1 | ISS | Homo_sapiens(9606) | Function |
| GO:0034189 | enables very-low-density lipoprotein particle binding | 1 | ISS | Homo_sapiens(9606) | Function |
| GO:0034190 | enables apolipoprotein receptor binding | 1 | IDA | Homo_sapiens(9606) | Function |
| GO:0036020 | located_in endolysosome membrane | 1 | TAS | Homo_sapiens(9606) | Component |
| GO:0042157 | involved_in lipoprotein metabolic process | 1 | IEA | Homo_sapiens(9606) | Process |
| GO:0042632 | involved_in cholesterol homeostasis | 1 | IMP | Homo_sapiens(9606) | Process |
| GO:0043523 | involved_in regulation of neuron apoptotic process | 1 | ISS | Homo_sapiens(9606) | Process |
| GO:0043525 | involved_in positive regulation of neuron apoptotic process | 1 | IMP | Homo_sapiens(9606) | Process |
| GO:0043621 | enables protein self-association | 1 | IDA | Homo_sapiens(9606) | Function |
| GO:0048471 | located_in perinuclear region of cytoplasm | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:0050750 | enables low-density lipoprotein particle receptor binding | 2 | IDA,IPI | Homo_sapiens(9606) | Function |
| GO:0070326 | enables very-low-density lipoprotein particle receptor binding | 1 | IDA | Homo_sapiens(9606) | Function |
| GO:1905596 | involved_in negative regulation of low-density lipoprotein particle receptor binding | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:1905598 | involved_in negative regulation of low-density lipoprotein receptor activity | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:1905601 | involved_in negative regulation of receptor-mediated endocytosis involved in cholesterol transport | 1 | IDA | Homo_sapiens(9606) | Process |
| GO:1990666 | part_of PCSK9-LDLR complex | 1 | IDA | Homo_sapiens(9606) | Component |
| GO:1990667 | part_of PCSK9-AnxA2 complex | 2 | IDA,IPI | Homo_sapiens(9606) | Component |
| GO:2000650 | involved_in negative regulation of sodium ion transmembrane transporter activity | 1 | IDA | Homo_sapiens(9606) | Process |